

Curriculum Vitae

Personal information Sofia Vaz

Work experience

-Since Oct 2016 – Nuclear Medicine Specialist, Nuclear Medicine-Radiopharmacology, Champalimaud Clinical Center, Champalimaud Foundation, Lisbon.

-Jan-Sep 2016 – Nuclear Medicine Specialist, Portuguese Institute of Oncology (Lisbon Center)

-Jan 2012 – Dec 2015 – Residency of Nuclear Medicine, Portuguese Institute of Oncology (Lisbon Center)

-Jan-Dec 2011 – General medical residency, Hospital de Santa Maria, Lisbon

Reporting nuclear medicine examinations (PET/CT and scintigraphies), regular participation in tumour boards/multidisciplinary meetings, writing scientific papers

Education and training

- June 2021 – started the PhD program about "Nuclear Medicine in Breast Cancer" at the Radiology department, Leiden University Medical Center. Supervisors: Prof. dr. Lioe-Fee de Geus-Oei and Prof. Maria João Cardoso
- Oct 2018 – Fellowship of the European Board of Nuclear Medicine (FEBNM)
- Jan 2012 – Dec 2015 – Residency of Nuclear Medicine, Portuguese Institute of Oncology (Lisbon Center). Supervisor: Dr. Teresa C. Ferreira; Director: Dr. Lucília Salgado
- Aug-Nov 2015 – Internship at the Nuclear Medicine Department, Hôpital Lariboisière and Hôpital Saint-Louis, Paris. Supervisor: Dr. Frédéric Paycha; Director: Prof. Laure Sarda / Prof. Ilana Peretti
- Jan-Dec 2011 – General medical residency, Hospital de Santa Maria, Lisbon
- 2004-2010 – Master's degree in Medicine (Bologna Process), Faculty of Medicine, University of Lisbon, Lisbon

Additional information

Publications

ORCID identifier: 0000-0003-4229-9349

<https://www.researchgate.net/profile/Sofia-Vaz-2>

<https://www.scopus.com/authid/detail.uri?authorId=57191347830>

<https://publons.com/researcher/1640861/sofia-carrilho-vaz/>

1. Vaz SC, Woll JPP, Cardoso F, Groheux D, Cook GJR, Ulaner GA, Jacene H, Rubio IT, Schoones JW, Peeters MV, Poortmans P, Mann RM, Graff SL, Dibble EH, de Geus-Oei LF. Joint EANM-SNMMI guideline on the role of 2-[¹⁸F]FDG PET/CT in no special type breast cancer : (endorsed by the ACR, ESSO, ESTRO, EUSOBI/ESR, and EUSOMA). Eur J Nucl Med Mol Imaging. 2024 Jul;51(9):2706-2732. doi: 10.1007/s00259-024-06696-9
2. Groheux D, Vaz SC, Ulaner GA, Cook GJR, Woll JPP, Mann RM, Poortmans P, Cardoso F, Jacene H, Graff SL, Rubio IT, Peeters MV, Dibble EH, de Geus-Oei LF. Joint EANM-SNMMI guidelines on the role of 2-[¹⁸F]FDG PET/CT in no special type breast cancer: differences and agreements with European and American guidelines. Eur J Nucl Med Mol Imaging. 2024 Jul;51(9):2701-2705. doi: 10.1007/s00259-024-06694-x
3. Ulaner GA, Vaz SC. Women's Health Update: Growing Role of PET for Patients with Breast Cancer. Semin Nucl Med. 2024 Mar;54(2):247-255. doi: 10.1053/j.semnuclmed.2024.01.007.
4. Ulaner GA, Vaz SC, Groheux D. Quarter-Century Transformation of Oncology: Positron Emission Tomography for Patients with Breast Cancer. PET Clin. 2024 Apr;19(2):147-162. doi: 10.1016/j.cpet.2023.12.002
5. Mankoff D, Balogová S, Dunnwald L, Dehdashti F, DeVries E, Evangelista L, Van Kruchten M, Vaz SC, Fowler A, Linden H, Ulaner GA. Summary: SNMMI Procedure Standard/EANM Practice Guideline for Estrogen Receptor Imaging of Patients with Breast Cancer Using 16α-[¹⁸F]Fluoro-17β-Estradiol PET. J Nucl Med. 2024 Feb 1;65(2):221-223. doi: 10.2967/jnumed.123.266938 Vaz SC, Graff SL, Ferreira AR, Debiase M, de Geus-Oei LF. PET/CT in Patients with Breast Cancer Treated with Immunotherapy. Cancers (Basel). 2023 May 5;15(9):2620. doi: 10.3390/cancers15092620.
6. Vaz SC, Oliveira C, Teixeira R, Arias-Bouda LMP, Cardoso MJ, de Geus-Oei LF. The current role of nuclear medicine in breast cancer. Br J Radiol. 2023 Sep;96(1149):20221153. doi: 10.1259/bjr.20221153.
7. Oliveira C, Oliveira F, Vaz SC, Marques HP, Cardoso F. Prediction of pathological response after neoadjuvant chemotherapy using baseline FDG PET heterogeneity features in breast cancer. Br J Radiol. 2023 Jun 1;96(1146):20220655. doi: 10.1259/bjr.20220655.
8. Greco C, Pares O, Pimentel N, Louro V, Morales J, Nunes B, Antunes I, Vasconcelos AL, Kocielek J, Castanheira J, Oliveira C, Silva A, Vaz S, Oliveira F, Carrasquinha E, Costa D, Fuks Z. Positron Emission Tomography-Derived Metrics Predict the Probability of Local Relapse After Oligometastasis-Directed Ablative Radiation Therapy. Adv Radiat Oncol. 2021 Dec 5;7(2):100864. doi: 10.1016/j.adro.2021.100864.
9. Vaz SC, Oliveira F, Herrmann K, Veit-Haibach P. Nuclear medicine and molecular imaging advances in the 21st century. Br J Radiol. 2020 Jun;93(1110):20200095. doi: 10.1259/bjr.20200095.

Projects

1-In the context of my PhD I am working on imaging quantification using FDG PET/MRI in patients with breast cancer in Maastricht medical university.

2- Between 2017-2020 I collaborated in a pre-clinical project that aimed to label anti-PD-L1-mAb with radionuclide for imaging PD-L1 expression in cancer at Champalimaud Foundation. A Material Transfer Agreement from Genentech-Roche (ID # OR-216490) was obtained in September 2017.

Memberships

- Since May 2024 – President of the General Assembly from the Portuguese Nuclear Medicine Society
- Since Apr 2021 – Associate Editor of the British Journal of Radiology
- Since Feb 2021 – Reviewer of the European Journal of Nuclear Medicine and Molecular Imaging
- Since Jan 2019 – Member of the European Association of Nuclear Medicine (EANM) Oncology&Theranostics Committee
- Since Nov 2018 – Member of the European Board of Nuclear Medicine (EBNM) examination committee

Other Relevant Information